Robert Evans Heithaus

Robert Evans Heithaus

Auto-generated profile, based on publicly available information

Robert Evans Heithaus

University of South Florida , Tampa, FL 33601

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2007 in Physical Review Letters
Verified
Journal Article
Closed access
PDF file
JMJoel Mobley
Joel Mobley
RHRobert Evans Heithaus
Robert Evans Heithaus
The ultrasonic attenuation coefficient, phase velocity, and group velocity spectra are reported for a suspension that supports negative group velocities. The suspension consists of plastic microspheres with an average radius of 80  μm in an aqueous medium at a volume fraction of 3%. The spectra are measured using a broadband method covering a range from 2 to 20 MHz. The suspension exhibits negative group delays over a band near 4.5 MHz, with the group velocity magnitude exceeding 4.3×108  m/s at one point. The causal consistency of these results is confirmed using Kramers-Kronig relations.

1 February 2015 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
RHR.E. Heithaus
R.E. Heithaus
MCM. Cura
M. Cura
KMK.B. Marashi
K.B. Marashi
JSJ.D. Sacks
J.D. Sacks
JMJ.D. Meler
J.D. Meler
YDY. Daoud
Y. Daoud

28 September 2018 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
MCMarco Cura
Marco Cura
EHEvans Heithaus
Evans Heithaus
To evaluate the safety and efficacy of transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma, a retrospective analysis of patients who underwent TACE utilizing up to one vial of LC BeadM1 (70–150 μm) embolics with doxorubicin was performed. If tumor devascularization was not achieved, up to one additional vial of LC Bead (100–300 μm) embolics with doxorubicin was subsequently administered. Ninety-four sessions of TACE were completed among 48 patients. After a mean follow-up of 182 days, complete response was achieved in 10 patients (21%), partial response in 19 (40%), stable disease in 8 (17%), and progressive disease in 10 (21%). Disease control was achieved in 79% of patients: 90% of patients treated with 70- to 150-μm embolics alone vs. 70% of patients treated with both sizes of embolics (P = 0.47). Pathologic examination revealed complete necrosis in 5 of 10 tumors in eight transplants. Overall survival at 3, 12, and 24 months was 100%, 94%, and 94%, respectively. The median progression-free survival was 282 days. In conclusion, drug-eluting bead TACE with 70- to 150-μm embolics alone or in combination with 100- to 300-μm embolics is safe and demonstrates good disease control, particularly with small, solitary tumors.

28 September 2018 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
Justin M. SacksJustin M. Sacks
Justin M. Sacks
EHEvans Heithaus
Evans Heithaus
AGAlexia Ghazi
Alexia Ghazi
MCMarco Cura
Marco Cura
This brief case presentation addresses an imaging phenomenon sometimes seen during chemoembolization, referred to the literature as vascular lakes or vascular lakes phenomenon. Other papers have discussed the clinical significance of this imaging pattern. We present a case of vascular lakes seen at the time of chemoembolization, with associated histologic findings after liver explantation. To the authors’ knowledge, this case represents the first histological correlative analysis of this imaging pattern.

7 October 2026 in The Oncologist
Verified
Journal Article
Open access
Robert CG Martin IIRobert CG Martin II
Robert CG Martin II
RWRebekah White
Rebekah White
MBMalcolm M Bilimoria
Malcolm M Bilimoria
GNGovindarajan Narayanan
Govindarajan Narayanan
MKMichael Kluger
Michael Kluger
CCCarlos H F Chan
Carlos H F Chan
Background: Irreversible electroporation (IRE) is used in selected patients with Stage III pancreatic ductal adenocarcinoma (PDAC), but its association with survival relative to standard-of-care (SOC) therapy remains uncertain. Methods: This multicenter observational study included 137 patients from the DIRECT registry: 99 treated within an IRE-based strategy and 38 receiving SOC without IRE. Overall survival (OS) from diagnosis was evaluated using propensity-score overlap weighting as the principal adjusted analysis. Conventional inverse probability of treatment weighting (IPTW), propensity-score matching, 3- and 6-month landmark analyses, and a time-dependent Cox model treating IRE as a time-varying exposure were sensitivity analyses. Restricted mean survival time (RMST) at 24 months was estimated. Results: Median time from diagnosis to enrollment was 8 months (IQR, 6-10) with IRE and 4 months (IQR, 3-6) with SOC (P < .0001). Unadjusted median OS was 28 months (95% CI, 23-33) and 15 months (95% CI, 12-21), respectively. Overlap weighting was associated with lower mortality with IRE (HR, 0.28; 95% bootstrap CI, 0.12-0.48). Twenty-four-month RMST was 21.22 vs 16.24 months, an absolute difference of 4.99 months (95% bootstrap CI, 1.15-8.12). The time-dependent analysis attenuated but retained the association (HR, 0.59; 95% bootstrap CI, 0.37-0.94). Other sensitivity analyses were directionally consistent. Conclusions: An IRE-based treatment strategy was associated with longer OS than SOC without IRE. Attenuation in the time-dependent analysis indicates that treatment timing and selection contributed to the observed difference. Given the nonrandomized design and potential residual confounding, these findings demonstrate association rather than an independent causal effect of IRE.

12 June 2023 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
SLSydney Levy
Sydney Levy
GSGevalin Srisooksai
Gevalin Srisooksai
SRSteven Robicsek
Steven Robicsek
RHRobert Evans Heithaus
Robert Evans Heithaus